Aurobindo Pharma Limited — Board Meeting, 06-02-2025: Outcome of Board Meeting

The Board of Directors has approved the standalone and consolidated financial results for the third quarter and nine-month period ended December 31, 2024. Key highlights include total revenue from operations of ₹82,013.1 Cr, a profit of ₹13,386.2 Cr, and earnings per share of ₹22.94. Additionally, the board has approved the re-appointment of Mr. Santanu Mukherjee as Non-executive and Independent Director for a five-year term and sanctioned the buyback of 80% equity ownership in Tergene Biotech Limited, which will then become a direct subsidiary. The company plans to enter into a power purchase agreement for solar energy.